Rexulti (Brexpiprazole) Approved For Schizophrenia & Depression (Adjunct)
Rexulti (Brexpiprazole) is a drug that was approved July 10, 2015 for the treatment of schizophrenia and as an adjunctive option for major depressive disorder. In clinical trials it was referred to as the chemical “OPC-34712” and is being marketed as a superior successor to Abilify (Aripiprazole) due to the fact that Abilify’s patent expired …